BioMarin Pharmaceutical Inc. Reports Inducement Grants

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN RAFAEL, Calif., Feb. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that on February 17, 2015, the compensation committee of BioMarin's board of directors approved the grant to 125 newly hired employees of 91,610 restricted share units in the aggregate and stock options to purchase 35,400 shares of common stock in the aggregate. A portion of these grants are special inducement grants to certain employees of Prosensa Therapeutics B.V. or an affiliate who are joining BioMarin's subsidiary following BioMarin's acquisition of Prosensa Holding N.V.

The stock options and restricted share units were granted pursuant to the BioMarin Pharmaceutical Inc. 2014 Inducement Plan, approved by the compensation committee of BioMarin's board of directors on December 17, 2014, and were granted as inducements material to the new employees entering into employment with BioMarin in accordance with NASDAQ Listing Rule 5635(c)(4).

Each of the stock options has an exercise price equal to $101.51, the closing price per share of BioMarin's common stock as reported by NASDAQ on February 17, 2015, the date of grant.

The restricted share units will vest in equal installments annually over four years on the anniversary of the grant date, assuming in each case the employee remains continuously employed by BioMarin as of such date. In addition, each of the options is an incentive stock option and will vest 6/48ths on the six month anniversary of the grant date and 1/48th per month thereafter for the 42 immediately following months, assuming in each case the employee remains continuously employed by BioMarin as of such date.

BioMarin is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include VIMIZIM® (elosulfase alfa) for MPS IVA, a product wholly developed and commercialized by BioMarin; Naglazyme® (galsulfase) for MPS VI, a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for MPS I, a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany and Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include drisapersen, an exon skipping oligonucleotide, which is currently undergoing regulatory submission for the treatment of Duchenne muscular dystrophy (exon 51), pegvaliase (PEGylated recombinant phenylalanine ammonia lyase, formerly referred to as BMN 165 or PEG PAL), which is currently in Phase 3 clinical development for the treatment of PKU; talazoparib (formerly referred to as BMN 673), a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer; reveglucosidase alfa (formerly referred to as BMN 701), a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 3 clinical development for the treatment of Pompe disease; BMN 111, a modified C-natriuretic peptide, which is currently in Phase 2 clinical development for the treatment of achondroplasia; BMN 044, BMN 045 and BMN 053, exon skipping oligonucleotides, which are currently in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (exons 44, 45 and 53), cerliponase alfa (formerly referred to as BMN 190), a recombinant human tripeptidyl peptidase-1 (rhTPP1), which is currently in Phase 1 clinical development for the treatment of CLN2 disorder, a form of Batten disease; BMN 270, an AAV-factor VIII vector, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of MPS IIIB.

For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

Forward Looking Statements

This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to plans, objectives and future events. BioMarin intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current expectations of the management of BioMarin as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among other, market risks. These and other risks are described in greater detail in BioMarin's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2012. Given these uncertainties, you should not place undue reliance on these forward-looking statements. BioMarin assumes no obligation to update its forward-looking statements, except as required by law.

BioMarin®, Naglazyme®, Kuvan®, Firdapse® and VIMIZIM® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 290

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 169

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 136

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading
Moody's Upgrades Phillips Edison to Baa2 Rating with Stability

Updated Category News Views 131

Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...

Continue Reading
Quantum Stocks Soar Amid Rumored Federal Investments

Updated Category News Views 222

Quantum Computing Stocks on the Rise Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) have experienced remarkable increases in pre-market trading. IonQ rose by 13.71%, Rigetti by 11.67%, and D-Wave surged by an impressive 15.90%. This surge comes as there are reports suggesting the federal government may be considering...

Continue Reading
Unlocking Success: How a One-Hour Morning Routine Can Transform Lives

Updated Category News Views 384

The Transformative Power of a Screen-Free Morning Jeff Bezos, the visionary behind Amazon, emphasizes the importance of a structured morning without distractions. His approach encourages starting the day without diving into screens, allowing for a calm and focused beginning. Understanding Bezos' Morning Ritual Instead of beginning his day with devices, Bezos opts for...

Continue Reading
Nokia's Strategic Moves: Infinera Acquisition and Stock Insights

Updated Category News Views 186

Nokia's Evolution in Telecom and Network Solutions Nokia Oyj is a global leader in telecom equipment and offers comprehensive network infrastructure solutions. While it once dominated the mobile phone market, Nokia has since repositioned itself as an essential player in the deployment and support of 5G and 4G networks. Its main competitor, Telefonaktiebolaget LM Ericsson,...

Continue Reading